Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

杜瓦卢马布银耳霉素医学肝细胞癌索拉非尼内科学肿瘤科置信区间癌症免疫疗法无容量易普利姆玛

作者

B. Sangro,Stephen L. Chan,Robin Kate Kelley,George Lau,Masatoshi Kudo,Wattana Sukeepaisarnjaroen,M. Yarchoan,Enrico N. De Toni,J. Furuse,Yoon‐Koo Kang,Peter R. Galle,Lorenza Rimassa,Alexandra Heurgué,Vincent C. Tam,Tu Van Dao,S.C. Thungappa,В. В. Бредер,Y. Ostapenko,María Reig,M. Makowsky,Michael Paskow,Charu Gupta,John F. Kurland,Alejandra Negro,Ghassan K. Abou‐Alfa,Sérgio Santos de Azevêdo,Maria Ignez Braghiroli,Gustavo Girotto,Arinilda Bragagnoli,Ricardo Branco,Adilson Faccio,Andrea Moretto,Nils Gunnar Skare,Jamille G. Dutra,Luciana Spillari Viola,Karina Vianna,Fernando Meton,Cláudia Vaz de Melo Sette,Amanda Faulhaber,Vincent C. Tam,Félix Couture,Jim Biagi,Hélène Castel,Karen Mulder,Yoo‐Joung Ko,Kevin Zbuk,Stephen Welch,Annie Beaudoin,Alexandra Heurgué,Éric Assenat,Isabelle Archambeaud,David Tougeron,Jean‐Marie Péron,Marine Gilabert,Jean‐Pierre Bronowicki,Stéphane Cattan,Jean‐Frédéric Blanc,Mohamed Bouattour,Jean‐Marc Phelip,Valérie Boige,Pierre Michel,Anne-Claire Frin,Enrico N. De Toni,Marie‐Luise Berres,Arndt Vogel,Thomas Berg,Thomas Jens Ettrich,Dirk Waldschmidt,H. Wedemeyer,Marcus‐Alexander Wörns,Michael Bitzer,Karl-Heinz Weiss,George Lau,Stephen L. Chan,Thomas Yau,Y. Tai,Ann Shing Lee,Satheesh Chiradoni Thungappa,Lokesh K. N,Vikas Sureshchand Ostwal,Kattimani Kiran Ashok,Sushant Mittal,Hari Om Goyal,Sankar Srinivasan,Ghanashyam Biswas,Mallavarapu Mohan,Sewanti Limaye,Nirav Asarawala,Lorenza Rimassa,Alfredo Falcone,Luca Gianni,Antonio Gasbarrini,Bruno Daniele,Antonio Avallone,Giovanni Luca Frassineti,Fausto Roila,Masatoshi Kudo,Tomokazu Kawaoka,Manabu Morimoto,Yasuhiro Takikawa,Naoya Kato,Tatsuya Yamashita,Yukio Osaki,Kenta Motomura,Ryosuke Tateishi,Kazuyoshi Ohkawa,Yoshiyuki Wada,Hideki Onishi,Naoki Sasahira,Yoshitaka Inaba,Masayuki Kurosaki,Kunihiko Tsuji,Yoshiyuki Takei,Takeshi Aramaki,Atsushi Hagihara,Junji Furuse,Kiyohide Kioka,Hironori Koga,Yutaka Sasaki,Kazushi Numata,Toshifumi Tada,Yasunori Kawaguchi,Seijin Nadano,Alexander Vasilyev,В. В. Бредер,Oleg Lipatov,Mikhail Dvorkin,Oleg Zarubenkov,С. И. Кутукова,Roman Ponomarev,K. Shostka,Anna Alyasova,Э. Э. Топузов,Alexey Severtsev,Yuryi Petrov,Д. В. Ерыгин,Б. А. Бердов,Yoon‐Koo Kang,Won Young Tak,Joong‐Won Park,Ho Yeong Lim,Jeong Heo,Jee Hyun Kim,Tae‐You Kim,Hye Jin Choi,María Varela,María Reig,Bruno Sangro,Carlos Gómez Martin,Carmen Guillén‐Ponce,Carlos López,Ann‐Lii Cheng,Yee Chao,Yin‐Hsun Feng,Long‐Bin Jeng,Chao‐Hung Hung,Ming‐Mo Hou,Jing‐Houng Wang,Chia‐Jui Yen,Wattana Sukeepaisarnjaroen,Patrapim Sunpaweravong,Chaiyut Charoentum,Suebpong Tanasanvimon,Ekaphop Sirachainan,Teerapat Ungtrakul,Naiyarat Prasongsook,Kunlatida Maneenil,Wittawat Jitpewngarm,Yurii Ostapenko,Denys Skoryi,Igor Bondarenko,Yaroslav Shparyk,Dmytro Trukhin,Yevhen Hotko,Grygorii Ursol,Anna Kryzhanivska,Ghassan K. Abou‐Alfa,Kabir Mody,Farshid Dayyani,Raed Moh’d Taiseer Al-Rajabi,Mark Yarchoan,Sunil Gandhi,Oxana Crysler,Aiwu Ruth He,J. N. Reeves,Nathan Bahary,Amit Mahipal,Robin Kate Kelley,Anirudha Dasgupta,Julie Rowe,Ramya Thota,Muhammad Shaalan Beg,Michael A. Morse,SUNGHEE CHOI,Todd S. Crocenzi,Bradley G. Somer,Thomas A. Abrams,Crystal S. Denlinger,Qian Zhang,Nisha Sharma,Tu Van Dao,Nguyễn Tiến Thịnh,Le Thi Tuyet Phuong

出处

期刊：Annals of Oncology [Elsevier]
日期：2024-02-19 卷期号：35 (5): 448-457 被引量：38

链接

annalsofoncology.org nih.govdoi.org

标识

DOI：10.1016/j.annonc.2024.02.005

摘要

In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.

求助该文献

最长约 10秒，即可获得该文献文件

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

今日热心研友